A Randomized, Parallel-Group, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous Xingnaojing for Acute Ischemic Stroke patients with Endovascular Thrombectomy

Phase 4

• Conditions: acute ischemic stroke

• Registration Number: ITMCTR2100004970
• Lead Sponsor: Beijing Tiantan Hospital, Capital Medical University

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 20 February 2023

Recruitment & Eligibility

• Status: Pending
• Sex: Male
• Target Recruitment: Not specified

Inclusion Criteria

1. Patients over 18 years old;
2. Acute ischemic stroke was diagnosed
3. MRA or CTA showed occlusion of anterior circulation arteries
4. Acute intravascular therapy (including simple intravascular therapy and bridging therapy) within 24 hours of onset
5. Randomization was completed within 24 hours after operation
6. ICF should be signed by patients or family members

Exclusion Criteria

1.Treated with Xingnaojing injection
2. Patients with transient ischemic attack
3. Patients with cerebral hemorrhage on imaging examination
4. Patients with vasculitis
5. ALTAST = 3 times of the upper limit of normal value, Cr = 2 times of the upper limit of normal value
6. Patients with a tendency of bleeding, and severe bleeding occurred within 3 months
7. Allergic to Xingnaojing, ethanol, glycerin or allergic constitution
8. Patients with pregnancy planning, pregnancy or lactation
9. Patients with severe heart, liver, kidney disease or malignant tumor, life expectancy < 3 months
10. Patients participating in other drug clinical studies
11. The patients who are not suitable for the clinical study (such as those with mental and mental disorders, etc.) are considered by the researchers.

Study & Design

• Study Type: Interventional study
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
good clinical outcomes;